Zobrazeno 1 - 10
of 23
pro vyhledávání: '"I N, Sychev"'
Autor:
l. V. Fedina, i. N. Sychev, K. V. Mirzaev, A. V. Vardanyan, S. V. Glagolev, A. A. Kachanova, P. O. Bochkov, R. V. Shevchenko, S. N. Tuchkova, I. V. Sychev, S. P. Abdullaev, D A. Sychev
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 20, Iss 1, Pp 19-26 (2024)
Aim. The aim of our study was to investigate the influence of polymorphic markers of CYP3A4*22 CYP3A4*22 (c.522-191C>T, rs35599367), CYP3A5*3 (c.219237A>G, rs776746), ABCB1 rs1045642 (c.3435T>C) and rs4148738 (c.2692-2236C>T) genes on the plasma conc
Externí odkaz:
https://doaj.org/article/895693a579cb4ad08184d9190f32a514
Autor:
I. N. Sychev, O. V. Ignatenko, S. V. Yakovlev, L. V. Fedina, E. N. Burmistrova, M. P. Suvorova, T. D. Rastvorova, E. V. Strigunkova, R. Kh. Mukhamadiev
Publikováno v:
Вестник анестезиологии и реаниматологии, Vol 21, Iss 1, Pp 24-34 (2024)
The objective was to study the risk factors, outcomes of infections caused by colistin-resistant K. pneumonia (CRKP) and to evaluate the sensitivity of these microorganisms to antibacterial agents to determine the most adequate antibiotic therapy opt
Externí odkaz:
https://doaj.org/article/29b1313ed1f545109536c7393ba3024f
Autor:
M. P. Suvorova, I. N. Sychev, O. V. Ignatenko, E. N. Burmistrova, S. S. Mirzakhamidova, L. V. Fedina, R. M. Vakolyuk, S. V. Yakovlev
Publikováno v:
Антибиотики и Химиотерапия, Vol 67, Iss 11-12, Pp 36-45 (2023)
Background. The difficulties of antibacterial therapy of infections caused by carbapenemase-producing gram-negative bacteria are associated with limited options for adequate therapy since, in addition to resistance to carbapenems and other beta-lacta
Externí odkaz:
https://doaj.org/article/6402443bc6a64d529baf12b520ab08d8
Autor:
L. V. Fedina, I. N. Sychev, T. D. Rastvorova, E. V. Strigunkova, A. A. Kachanova, Z. A. Sozaeva, P. O. Bochkov, A. V. Vardanyan, K. B. Mirzayev, D. A. Sychev
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 18, Iss 6, Pp 624-629 (2023)
Aim. To investigate the effect of ABCB1 gene carriage and interdrug interactions on apixaban pharmacokinetics and clinical outcomes in patients with atrial fibrillation and deep vein thrombosis.Material and methods. Patients hospitalized at Yudin Sta
Externí odkaz:
https://doaj.org/article/547d7b56152449b99e64946f0dcd6d76
Autor:
А. О. Bykov, M. P. Suvorova, D. N. Protsenko, Sergey V. Yakovlev, O. V. Ignatenko, E. N. Burmistrova, I. N. Sychev, N. P. Krotenko
Publikováno v:
Вестник интенсивной терапии, Iss 2 (2023)
АКТУАЛЬНОСТЬ: Создание протоколов эффективной эмпирической антимикробной терапии невозможно без анализа актуальных данных чувствите
Externí odkaz:
https://doaj.org/article/6bb48c2cfb8f437e84cd2716b712720d
Autor:
I. N. Sychev, L. V. Fedina, A. S. Osipov, I. I. Temirbulatov, O. Yu. Tataroy, Zh. A. Sozaeva, K. A. Akmalova, N. P. Denisenko, S. P. Abdullaev, A. A. Kachanova, E. A. Grishina, K. B. Mirzaev, D. A. Sychev
Publikováno v:
Медицинский совет, Vol 0, Iss 4, Pp 41-46 (2021)
Introduction. Apixaban is a direct oral anticoagulant prescribed for treatment and prevention of venous thromboembolism (VTE) and for prevention of stroke in patients with nonvalvular atrial fibrillation. Direct oral anticoagulants (DOACs) such as ap
Externí odkaz:
https://doaj.org/article/5ad7ad0be6504c7ca0446a126b130503
Autor:
S. V. Yakovlev, M. P. Suvorova, A. O. Bykov, S. V. Zhuravel, K. A. Popugaev, L. Yu. Kulagina, I. N. Ochakovskaya, M. G. Fedorova, O. V. Pribytkova, A. A. Zateyshchikova, O. G. Malkova, T. N. Malorodova, E. S. Nekaeva, N. G. Ogonkin, Yu. A. Strezh, I. N. Sychev, O. I. Tazieva, S. G. Fominykh
Publikováno v:
Антибиотики и Химиотерапия, Vol 65, Iss 11-12, Pp 49-58 (2021)
The aim of the study was to evaluate the effectiveness of cefepime/sulbactam in patients with intra-abdominal infection, nosocomial pneumonia (NP) or ventilator-associated pneumonia (VAP) in actual clinical practice. Material and methods. The study w
Externí odkaz:
https://doaj.org/article/a99b4fea45ec4f7ebd0101f21d7b02c1
Autor:
K. B. Mirzaev, D. V. Ivashchenko, I. V. Volodin, E. A. Grishina, K. A. Akmalova, A. A. Kachanova, A. I. Skripka, R. M. Minnigulov, T. E. Morozova, O. A. Baturina, A. N. Levanov, T. V. Shelekhova, A. I. Kalinkin, D. A. Napalkov, A. A. Sokolova, D. A. Andreev, I. N. Sychev, P. O. Bochkov, D. A. Sychev
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 16, Iss 5, Pp 670-677 (2020)
Aim. To search for new pharmacogenetic biomarkers of bleeding risk in patients taking rivaroxaban and dabigatran for different indications: atrial fibrillation, endoprosthesis of large joints of lower limbs.Material and methods. The study enrolled 29
Externí odkaz:
https://doaj.org/article/060e30356f7741b38e1ef181c3cd5e48
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 16, Iss 5, Pp 699-705 (2020)
Aim. A meta-analysis of studies on the CES1 gene c.1168-33A>C polymorphism (rs2244613) carriage influence on the equilibrium concentration and the risk of bleeding during dabigatran taking.Material and methods. The search was carried out in the Russi
Externí odkaz:
https://doaj.org/article/1620c53a071141f9bd0579f78f674571
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4S, Pp 39-46 (2020)
Impaired kidney function may influence pharmacokinetics of most of the drugs, including the ones used in COVID-19. In this publication, the most important pharmacokinetic parameters and dose adjustment approaches are provided, based on The Renal Drug
Externí odkaz:
https://doaj.org/article/eefaef53ceca4ec982953d6774cca397